CN Mobile Logo

Search form


Taxotere for Anthracycline Refractory Advanced Breast Cancer

Taxotere for Anthracycline Refractory Advanced Breast Cancer

COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) is now available for treatment of patients with locally advanced or metastatic breast cancer that has progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy.

In clinical studies, Taxotere has shown the highest response rate ever (47%) for a single agent in this patient population at a dose of 100 mg/m² given IV over 1 hour every 3 weeks, "a very convenient administration schedule," Howard A. Burris III, MD, of the Cancer Therapy and Research Center, San Antonio, said at a teleconference held to launch the new product.

Dr. Burris noted that "with a drug with this much impact in shrinking tumors in the advanced stage, the hope is that we will eventually be able to bring it into stage I, II, and III treatment, and those clinical trials are ongoing."

The pivotal Taxotere trials were reported in this publication in Nov 1995, page 1, and June 1996, page 16.

By clicking Accept, you agree to become a member of the UBM Medica Community.